Abbott's business, financial condition, results of operations, or prospects could be materially adversely affected by various risks, including the ability to respond effectively to environmental disruptions and transform itself to emerge stronger from challenging situations. The company may pursue acquisitions, licensing arrangements, and strategic alliances as part of its business strategy, which could incur significant expenses and negatively affect profitability. Abbott's operations are subject to numerous governmental regulations, and compliance can be costly and time-consuming, impacting organizational health and operational continuity. The company must incur expenses and spend time to ensure compliance with complex regulations, which could disrupt its business and have a material adverse effect on revenues, profitability, and financial condition. Changes in the health care regulatory environment may adversely affect Abbott's business, impacting demand for products and pricing. The expiration or loss of patent protection and licenses may also affect future revenues and operating income, as Abbott relies on intellectual property protection to compete effectively. The company faces intense competition, and the introduction of competitors' products may negatively affect its results of operations. Manufacturing processes are complex and subject to various risks, including equipment malfunction and environmental factors, which could lead to increased costs and lost revenue. Significant safety concerns could arise for Abbott's products, which may result in product liability claims and lawsuits, adversely affecting its business and reputation. The economic position and credit quality of certain countries may negatively impact Abbott's results of operations, with unfavorable economic conditions potentially increasing collection times for outstanding trade receivables. The international nature of Abbott's business subjects it to additional risks that may cause revenue and profitability to decline. The company monitors economic conditions and customer creditworthiness, establishing allowances against trade receivables when necessary. Abbott's operations in Venezuela are affected by hyper-inflation and political uncertainty, which could impact future operating results. The company has invested in its information technology systems to reduce the risk of cyber attacks, but there can be no assurance that these measures will prevent future interruptions. Abbott's management has approved plans to streamline operations to reduce costs and improve efficiencies, reflecting a commitment to organizational resilience through strategic initiatives. The company continues to focus on developing differentiated technologies and expanding its product portfolio in high-growth markets, which is essential for maintaining competitive advantage and operational flexibility. In 2015, Abbott's revenues were driven primarily by established pharmaceuticals, nutritional, and diagnostics businesses, with significant growth in emerging markets. The company plans to continue building its product portfolio and expanding in high-growth emerging markets while implementing margin improvement initiatives. Future planning includes focusing on obtaining additional product approvals and increasing penetration in emerging markets. Overall, Abbott's strategic response to external pressures and operational challenges reflects its commitment to organizational resilience and adaptability in a complex and dynamic business environment.